Genmab's petosemtamab cuts death risk by half in head and neck cancer trial
Danish drugmaker Genmab reported its experimental drug petosemtamab reduced the risk of death by 50% in a late-stage study of patients with head and neck cancer, sending US-traded shares up 28%.
